| 肽胺哌啶酮联合TACE治疗原发性肝癌后免疫功能的变化 |
| 投稿时间：2011-08-24 点此下载全文 |
| 引用本文：苏小琴,姚登福,徐爱兵,王建红,于洪波,谭清和.肽胺哌啶酮联合TACE治疗原发性肝癌后免疫功能的变化[J].医学研究杂志,2012,41(5):135-137 |
| DOI：
|
| 摘要点击次数: 1203 |
| 全文下载次数: 774 |
|
|
| 中文摘要:目的探讨肽胺哌啶酮联合TACE对原发性肝癌免疫功能和生存质量的影响。方法治疗组A37例采用肽胺哌啶酮联合TACE治疗，治疗组B35例单纯行TACE术，对照组30例为健康志愿者。分别于治疗前1天和治疗后2周、4周测定外周血T细胞亚群，并与30例正常人对照组作比较。同时观察患者的体重和KPS评分，进行对照研究。结果治疗组A和B的CD3+、CD4+、CD4+/CD8+和CD3-CD56+NK，在治疗前无明显差异，但与正常对照比较，CD3+、CD4+、CD4+/CD8+和CD3-CD56+NK水平较对照组显著降低（P<0.05）。A组治疗后2周CD3+、CD4+、CD4+/CD8+和CD3-CD56+NK水平均较治疗前明显升高,治疗后4周CD3+、CD4+、CD4+/CD8+和CD3-CD56+NK水平已部分接近正常。B组的免疫功能的恢复较慢，2周时略升高，但无统计学差异，4周时显著升高。治疗组A的KPS评分高于B组，有显著差异。结论肝癌患者细胞免疫功能处于抑制状态,TACE对细胞免疫功能影响较小,随着肿瘤负荷减小,细胞免疫功能显著提高。肽胺哌啶酮能改善肝癌患者的细胞免疫功能和生存质量。 |
| 中文关键词:肽胺哌啶酮 中晚期肝癌 免疫功能 |
| |
| HCC Patients Immunity after Treatment with Thalidomide Combined with Transcatheter Arterial Chemoembolization |
|
|
| Abstract:ObjectiveTo explore the effect of thalidomide on the immunity and quality of life of HCC patients after TACE. MethodsPatients were devided into two groups randomly. Group A (37cases)was treated with thalidomide and TACE. Group B(35cases) was treated with TACE only. 30 healthy volunteers were regarded as control group.CD3+,CD4+ and CD4+/CD8+CD3-CD56+NK levels were detected with FCM before treatment and two weeks,four weeks later after treatment. Three groups were compared for weight and KPS cores. ResultsThere was no difference in CD3+,CD4+,CD4+/CD8+and CD3-CD56+NK between two groups.While levels of the above indicators in treated groups including A and B were lower than those of control group. But after treatment, T cell subsets of group A got right while group B on the low side. KPS of group A was higher than that of B. ConclusionThalidomide could improve the immunity and quality of life of HCC patients. |
| keywords:Thalidomide HCC Immunity |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
